EPS Bio Technology Corp.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
EPS Bio Technology Corp. (4183) - Total Assets
Latest total assets as of December 2024: NT$541.89 Million TWD
Based on the latest financial reports, EPS Bio Technology Corp. (4183) holds total assets worth NT$541.89 Million TWD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EPS Bio Technology Corp. - Total Assets Trend (2019–2024)
This chart illustrates how EPS Bio Technology Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
EPS Bio Technology Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
EPS Bio Technology Corp.'s total assets of NT$541.89 Million consist of 67.9% current assets and 32.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 23.8% |
| Accounts Receivable | NT$153.56 Million | 28.3% |
| Inventory | NT$81.06 Million | 15.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how EPS Bio Technology Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EPS Bio Technology Corp.'s current assets represent 67.9% of total assets in 2024, an increase from 62.3% in 2019.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, down from 32.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 28.3% of total assets.
EPS Bio Technology Corp. Competitors by Total Assets
Key competitors of EPS Bio Technology Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
EPS Bio Technology Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - EPS Bio Technology Corp. generates 0.83x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, EPS Bio Technology Corp. generates $ 3.19 in net profit.
EPS Bio Technology Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.83 | 2.93 | 3.62 |
| Quick Ratio | 2.21 | 2.35 | 2.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$238.15 Million | NT$ 241.30 Million | NT$ 248.59 Million |
EPS Bio Technology Corp. - Advanced Valuation Insights
This section examines the relationship between EPS Bio Technology Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | NT$541.89 Million |
| Market Capitalization | $4.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values EPS Bio Technology Corp.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: EPS Bio Technology Corp.'s assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for EPS Bio Technology Corp. (2019–2024)
The table below shows the annual total assets of EPS Bio Technology Corp. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$541.89 Million | -0.23% |
| 2023-12-31 | NT$543.16 Million | +2.92% |
| 2022-12-31 | NT$527.76 Million | -8.60% |
| 2021-12-31 | NT$577.45 Million | +5.57% |
| 2020-12-31 | NT$546.97 Million | +2.31% |
| 2019-12-31 | NT$534.61 Million | -- |